High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma

• Published in: World journal of surgical oncology Vol. 12; no. 1; p. 287
• Main Authors: Hu, Fei, Wang, Wei, Zhou, Hang-Cheng, Shang, Xi-Fu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.09.2014; BioMed Central
• Subjects: Adolescent; Adult; Analysis; Biomarkers, Tumor - metabolism; Biotechnology industry; Bone cancer; Bone Neoplasms - metabolism; Bone Neoplasms - mortality; Bone Neoplasms - pathology; Cell Adhesion Molecules - metabolism; Child; Disease Progression; Female; Follow-Up Studies; Hospitals; Humans; Immunoenzyme Techniques; Kinases; Lymphatic Metastasis; Male; Medical imaging; Medical prognosis; Medical records; Medical research; Medicine, Experimental; Metastasis; Middle Aged; Multivariate analysis; Neoplasm Staging; NMR; Nuclear magnetic resonance; Orthopedics; Osteochondroma - metabolism; Osteochondroma - mortality; Osteochondroma - pathology; Osteosarcoma - metabolism; Osteosarcoma - mortality; Osteosarcoma - secondary; Patients; Prognosis; Proteins; Rodents; Studies; Survival Rate; Young Adult; China
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/1477-7819-12-287

Recent studies have found that periostin (PN), as a kind of secreted glycoprotein, is closely related to the metastatic potential and prognosis of many kinds of tumors. This study aimed to examine the expression of PN in patients with osteosarcoma and explore the relationship of PN expression with clinicopathologic factors and prognosis. PN was detected by histopathological and immunohistochemical methods in 62 cases of osteosarcoma and 62 of osteochondroma. Detailed pathological and clinical data were collected by reviewing medical records. The results showed that increased PN protein expression was prevalent in osteosarcoma and was significantly associated with pathologic subtype (P =0.000), tumor size (P =0.016) and Enneking stage (P =0.047). Additionally, expression of PN was found to be an independent prognostic factor in osteosarcoma patients. High expression of PN protein is closely correlated to the tumor progression and poor survival of osteosarcoma. Our data suggest that PN is a promising biomarker for identifying individuals with poor prognostic potential and suggests its possible use as a prognostic marker in patients with osteosarcoma.